We could not find any results for:
Make sure your spelling is correct or try broadening your search.
Register to chat with like-minded investors on our interactive forums.
| Share Name | Share Symbol | Market | Type |
|---|---|---|---|
| Pfizer Inc | NYSE:PFE | NYSE | Common Stock |
| Price Change | % Change | Share Price | High Price | Low Price | Open Price | Shares Traded | Last Trade | |
|---|---|---|---|---|---|---|---|---|
| 0.01 | 0.04% | 25.63 | 55,866 | 10:54:59 |
From May 2019 to May 2024
By Tess Stynes
Pfizer Inc. (PFE) said its injectable drug for small-for-gestational-age children showed statistically significant increases in height after 24 months in a Phase 3B study.
The study was intended to generate additional data regarding the safety and efficacy of Genotropin in children born small-for-gestational-age who fail to achieve catch-up growth by two years of age.
In the study, which included children between ages 24 months and 30 months, those receiving the drug showed statistically significant improvement over those who didn't.
Genotropin has U.S. Food and Drug Administration approval to treat children who don't make enough growth hormone on their own, those with genetic conditions such as Prader-Willi syndrome and Turner syndrome, those born smaller than most other babies and those with idiopathic short stature. The drug also is approved for adults with growth hormone deficiency.
Write to Tess Stynes at tess.stynes@wsj.com
Subscribe to WSJ: http://online.wsj.com?mod=djnwires
1 Year Pfizer Chart |
1 Month Pfizer Chart |
It looks like you are not logged in. Click the button below to log in and keep track of your recent history.
Support: +44 (0) 203 8794 460 | support@advfn.com
By accessing the services available at ADVFN you are agreeing to be bound by ADVFN's Terms & Conditions
Hot Features
Premium
